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Association Between Antimicrobial Prophylaxis With Double-Dose Cefuroxime
and Surgical Site Infections in Patients Weighing 80 kg or More
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Abstract
IMPORTANCE Many guidelines recommend a weight-adopted dose increase of cefuroxime for
surgical antimicrobial prophylaxis (SAP). However, the evidence that this approach is associated with
lower rates of surgical site infection (SSI) is limited.
OBJECTIVE To assess whether double-dose cefuroxime SAP was associated with a decreased SSI
rate in patients weighing at least 80 kg.
DESIGN, SETTING, AND PARTICIPANTS This cohort study included adult patients (>18 years)
weighing at least 80 kg who underwent 9 major surgical procedures with a cefuroxime SAP
administration from the Swissnoso SSI surveillance system between January 2015 and December
2019 at 142 Swiss hospitals. The follow-up was 30 days for all surgical procedures and 1 year for
implant-related operations.
EXPOSURES Cefuroxime SAP dose (1.5 vs 3.0 g).
MAIN OUTCOMES AND MEASURES Overall SSI. A mixed-effects logistic regression adjusted for
institutional, epidemiological, and perioperative variables was applied. Results were stratified by
weight categories as well as by wound contamination classes.
RESULTS Of 41 076 eligible patients, 37 640 were included, with 22 625 (60.1%) men and a median
(IQR) age of 61.9 (49.9-71.1) years. The outcome SSI was met by 1203 patients (3.2%). Double-dose
cefuroxime was administered to 13 246 patients (35.2%) and was not significantly associated with a
lower SSI rate (adjusted odds ratio [aOR], 0.89; 95% CI, 0.78-1.02; P = .10). After stratification by
weight category, double-dose SAP vs single-dose SAP was associated with lower SSI rates among
16 605 patients weighing at least 80 to less than 90 kg (aOR, 0.76; 95% CI, 0.61-0.97; P = .02) but
not in the other weight categories (90 to <100 kg, 10 342 patients: aOR, 1.12; 95% CI, 0.87-1.47;
P = .37; 100 to <120 kg, 8099 patients: aOR, 0.99; 95% CI, 0.76-1.30; P = .96; 120 kg, 2594
patients: aOR, 0.65; 95% CI, 0.42-1.04; P = .06). After stratification by contamination class, double-
dose SAP was associated with lower SSI rates among 1946 patients with contaminated wounds (aOR,
0.49; 95% CI, 0.30-0.84; P = .008) but not those with clean wounds (25 680 patients; aOR, 0.92;
95% CI, 0.76-1.12; P = .44) or clean-contaminated wounds (10 014 patients; aOR, 0.90; 95% CI, 0.73-
1.12; P = .37) compared with a single dose.
CONCLUSIONS AND RELEVANCE In this study, double-dose SAP with cefuroxime for patients
weighing at least 80 kg was not consistently associated with a lower SSI rate.
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Key Points
Question Is double-dose cefuroxime
surgical antimicrobial prophylaxis
associated with a lower surgical site
infection rate in patients weighing at
least 80 kg?
Findings In this cohort study of 37 640
patients who underwent 9 major
surgical procedures, there was no
significant overall association between
single-dose vs double-dose cefuroxime
and the outcome of surgical site
infection.
Meaning These findings suggest that
double-dose cefuroxime prophylaxis for
patients weighing at least 80 kg may
not be associated with a lower surgical
site infection rate.
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Author affiliations and article information are
listed at the end of this article.
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Introduction
Surgical site infections (SSIs) account for approximately 20% of all health care–associated
infections1,2 and have a major impact on morbidity and mortality.3,4 Several national and international
guidelines provide evidenced-based measures to reduce SSI risk. Surgical antimicrobial prophylaxis
(SAP) administration, its correct timing, and redosing have been identified as critical items for SSI
prevention.4-8
While weight-adapted application of antimicrobial agents has been implemented in some
infectious disease areas,9,10 this practice has not been widely implemented for SSI prevention.4-8
Currently, double-dose SAP administration has been shown to reduce SSI for patients weighing at
least 120 kg, but all studies had sample sizes of less than 200 patients.11-15 In line with these findings,
preliminary data suggest a role of double-dose SAP in reducing the SSI rate in patients who weigh at
least 80 kg.16 Nevertheless, in most guidelines for SSI prevention, the issue of weight-adjusted SAP
dosing is still considered unresolved.4-8
Even after the introduction of a nationwide SSI surveillance program, the Swiss SSI rate
remained at an elevated level compared with results from other national surveillance programs.17 To
further decrease the rate, Swissnoso, the national center for infection control, issued national
guidelines in 2015 advocating the optional increase of the SAP standard dose for patients weighing
at least 80 kg as part of interventions aiming at decreasing SSI rates.7 The aim of this study was to
evaluate the association of the introduction of this recommendation in 2015 with SSI rates in
Switzerland among patients weighing at least 80 kg, based on data from the Swiss nationwide
surveillance program.
Methods
SSI surveillance by Swissnoso is mandated by Swiss health care policies and is considered a quality
improvement project. All patients were informed about their automatic inclusion in SSI surveillance
on admission and given the opportunity to opt out. Summary results of the SSI incidences are
published yearly.18 The Bernese Cantonal human subjects committee approved risk factors analyses
within the SSI surveillance database. This study follows the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting guideline.
Study Design and Setting
This is a multicenter cohort study of prospectively collected data from the Swiss national SSI
surveillance program.17,19 We included data from 142 health care institutions in Switzerland between
January 2015 and December 2019. Each participating hospital records surveillance data on a
minimum of 3 different intervention types during a selected period and then includes all patients.17
Patients can opt out, but this is a rare exception (<1%). The surveillance includes data collection at
discharge as well as rigorous postdischarge surveillance 30 days after the intervention, with
additional medical record review in case of suspected infection.17 For implant surgery, a second
follow-up occurs after 1 year. All patients were contacted at least 5 times before being considered lost
to follow-up. The overall follow-up for routine postdischarge surveillance was greater than 91%.17
Data were then entered in the national database. Staff members of the Swissnoso SSI surveillance
team periodically performed on-site audits to check data quality, as published elsewhere.17,19,20
Participants
Inclusion criteria were (1) participation in the surveillance program, (2) undergoing 1 of the 9 most
frequent surgical interventions (hernia repair, knee or hip implant, cardiac surgery, laminectomy,
colon surgery, cholecystectomy, cesarean delivery, and gastric bypass), (3) the procedure taking
place between 2015 and 2019, (4) documented weight at the time of surgery of at least 80 kg, (5)
being older than 18 years, and (6) a cefuroxime (with or without metronidazole) SAP administration
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of 1.5 or 3.0 g in the 120 minutes before incision. Exclusion criteria were patients with preexisting
infections (ie, wound contamination class IV), missing data on SAP, and patients for whom no
complete follow-up was available (Figure).
Variables, Outcomes, and Data Sources
The primary outcome was any SSI (superficial or deep incisional infection and/or organ space
infection) at 30 days and/or 1 year. Covariables included age; body mass index (BMI; calculated as
weight in kilograms divided by height in meters squared); American Society of Anesthesiologists
(ASA) score; wound contamination class: clean (class I), clean-contaminated (class II), or
contaminated (class III); year of surgery; emergency procedure; time from SAP administration to
incision (per 30 minutes); procedure duration longer than standard time; and hospital bed-size. The
decision of single-dose vs double-dose SAP was in many cases decided at the level of the institution.
In some institutions, however, this was also at the discretion of the surgeon and/or anesthesiologist
in charge.
SSI cases were defined as patients with SSI according to US Centers for Disease Control and
Prevention (CDC) definitions.21 Surveillance staff reviewed all patient data, and those patients with a
suspected SSI were crosschecked by a dedicated physician. All supervising physicians—most board-
certified in infectious diseases—had attended a training course on SSI surveillance.
Data were electronically entered into a centralized database. Type of SSI (ie, superficial
incisional, deep incisional, or organ space) was recorded as well as the pathogen (if available).
Primary data were obtained from the patient medical records and telephone interviews with
patients. The data source for the variables was the Swissnoso SSI surveillance program.
To analyze the consequences of preoperative comorbidity, ASA scores were grouped into low
(1-2) and high score (3-5). Regarding bed size, hospitals were grouped into those with fewer than
200 beds, 200 to 500 beds, and more than 500 beds.
Statistical Analysis
To investigate differences in terms of baseline characteristics for those with single- and double-dose
SAP, we used the χ2 or Wilcoxon tests for categorical and continuous data, respectively. We then
calculated the SSI outcome for the individual interventions by single vs double SAP dosing. To
determine the association between SAP dosing and SSI, we fitted covariate-adjusted, multilevel
logistic regression models with clustering at the intervention level (random intercept).
Two stratified analyses, adjusted for the covariables, were performed for weight group and
contamination class. A subgroup analysis excluded surgeries with a 1-year follow-up period. End
point missingness resulting from patients being lost to follow-up was investigated by comparing the
characteristics of the included cases with those patients lost to follow-up to determine whether there
were systematic differences between the 2 groups. A 2-tailed P < .05 was considered statistically
Figure. Flowchart of Patient Inclusion
41 076 Adult patients
9 Common surgical procedures
142 Swissnoso SSI Surveillance hospitals,
January 2015 to December 2019
26 250 Received single-dose cefuroxime
(1.5 g) (65%) 
14 556 Received double-dose cefuroxime
(3 g) (35%)
24 394 Patients with single-dose
included in analysis (65%)
13 246 Patients with double-dose
included in analysis (35%)
1856 Lost to follow-up (8.1%) 1310 Lost to follow-up (9.0%)
SSI indicates surgical site infection.
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significant throughout. All statistics were performed in R version 4.0.2 (R Project for Statistical
Computing).
Results
We included 37 640 patients, with 22 625 (60.1%) men and a median (IQR) age of 61.9 (49.9-71.1)
years. SAP was administered as single dose in 24 394 patients (64.8%) and double dose in 13 246
patients (35.2%) (Figure). The detailed baseline patient and procedural characteristics stratified by
SAP dosing are shown in Table 1. Patients from higher weight groups, those with higher ASA scores,
and those receiving care at larger hospitals were more likely assigned to the double-dose SAP group.
Also, an increasing number of double-dose SAP was given throughout the study period (Table 1).




Single dose (1.5 g)
(n = 24 394)
Double dose (3.0 g)
(n = 13 246)
Age, median (IQR) 62.2 (49.7 to 71.2) 61.3 (50.1 to 70.7) .03
Sex
Male 13 993 (57.4) 8632 (65.2) <.001
Female 10 401 (42.6) 4614 (34.8) <.001
BMI, median (IQR)a 30.8 (28.1 to 34.3) 31.6 (28.3 to 36.3) <.001
ASA scores
1-2 16 806 (68.9) 7403 (55.9)
<.0013-5 7477 (30.7) 5769 (43.6)
NA 111 (0.5) 74 (0.6)
Intervention type
Total knee prosthesis 6606 (27.1) 2112 (15.9)
<.001
Total hip prosthesis 6222 (25.5) 2751 (20.8)
Cardiac surgery 1045 (4.3) 2484 (18.8)
Colon surgery 2226 (9.1) 1040 (7.9)
Hernia repair 1879 (7.7) 873 (6.6)
Cesarean delivery 2818 (11.6) 220 (1.7)
Cholecystectomy 1574 (6.5) 839 (6.3)
Laminectomy 872 (3.6) 968 (7.3)
Gastric bypass surgery 1152 (4.7) 1959 (14.8)
Wound contamination class
I, clean 16 543 (67.8) 9137 (69.0)
<.001II, clean-contaminated 6365 (26.1) 3649 (27.5)
III, contaminated 1486 (6.1) 460 (3.5)
Elective surgery 21 781 (89.3) 11 949 (90.2) .006
SAP administration prior to incision,
median (IQR), min
−38 (−50 to −25) −39 (−50 to −28) <.001
Surgery exceeding standard time 4657 (19.1) 1936 (14.6) <.001
Year
2015 1655 (6.8) 366 (2.8)
<.001
2016 7517 (30.8) 2484 (18.8)
2017 7592 (31.1) 4200 (31.7)
2018 5666 (23.2) 4514 (34.1)
2019 1964 (8.1) 1682 (12.7)
Hospital size, beds
<200 15 411 (63.2) 6966 (52.6)
<.001200-499 7453 (30.6) 3367 (25.4)
≥500 1530 (6.3) 2913 (22.0)
Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); NA, not available; SAP, surgical antimicrobial
prophylaxis.
a Data missing for 2125 patients in the single-dose
group (8.7%) and 64 in the double-dose
group (0.4%).
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The overall rate of SSI was 3.2% (1209 patients), with 747 SSIs (3.1%) occurring in the single-
dose group, and 462 (3.5%) in the double-dose group (P = .76). There were no differences in the
crude SSI rates between the 2 groups, stratified for the individual interventions (Table 2). In the
adjusted multilevel model, the double SAP dose was not significantly associated with a decreased SSI
rate (adjusted odds ratio [aOR], 0.89; 95% CI, 0.78-1.02; P = .10). Covariables independently
associated with a higher SSI risk were BMI (aOR per 1-unit increase, 1.05; 95% CI, 1.04-1.07; P < .001),
ASA score of 3 to 5 (compared with ASA score of 1-2; aOR, 1.48; 95% CI, 1.27-1.72; P < .001), hospital
with 200 to 499 beds (compared with <200 beds: aOR, 1.24; 95% CI, 1.07-1.43; P = .004), and
procedures longer than standard operation time (aOR, 1.55; 95% CI, 1.35-1.78; P < .001). In contrast,
elective surgery (aOR, 0.76; 95% CI, 0.63-0.92; P < .001) was significantly associated with a
decreased SSI risk (Table 3).
Given that we detected significant interactions between double-dose SAP and weight class as
well as double-dose SAP and contamination class, we proceeded with stratified analyses. First, we
stratified for weight categories. Among the 16 605 patients weighing at least 80 and less than 90 kg,
double-dose SAP was significantly associated with a lower SSI rate (aOR, 0.76; 95% CI, 0.61-0.97;
P = .02). In contrast, double-dose SAP was not associated with lower SSI rate in the 10 324 patients
weighing at least 90 and less than 100 kg (aOR, 1.12; 95% CI, 0.87-1.47; P = .37), nor among the 8099
patients weighing at least 100 and less than 120 kg (aOR, 0.99; 95% CI, 0.76-1.30; P = .96), nor
among the 2594 patients weighing at least 120 kg (aOR, 0.65; 95% CI, 0.42-1.01; P = .06) (Table 4).
Next, we stratified for wound contamination class. Double-dose SAP was significantly
associated with a lower SSI rate within the 1946 patients (5.2%) with contaminated wounds (aOR,
0.49; 95% CI, 0.30-0.84; P = .008) but not among the 25 680 patients (68.2%) with clean wounds
(aOR, 0.92; 95% CI, 0.76-1.12; P = .44), nor among the 10 014 patients (26.6%) patients with clean-
contaminated wounds (aOR, 0.90; 95% CI, 0.73-1.12; P = .37) (eTable 1 in Supplement 1).
Supplementary analyses of the complete data set with the outcome being complex SSI (deep
wound infection and organ space infection) as well as wound infections (superficial and deep)
yielded similar results as the main analysis (eTable 2 in Supplement 1). An additional analysis
comparing the 10 264 patients weighing at least 80 kg in the database receiving 2 g of cefazoline
with the 1073 patients receiving 3.0 g of cefazoline also showed similar results (eTable 3 in
Supplement 1). Results of adjusted generalized logistic models, stratified by surgical procedure, are
shown in eTable 4 in Supplement 1.
In a subgroup analysis, we excluded surgical procedures with implant that led to a second
follow-up after 1 year (cardiac surgery as well as hip/knee implant surgery). In this fully adjusted
model of the remaining 15 809 patients and complete records, cefuroxime double dose was
significantly associated with a lower risk of SSI (aOR, 0.83; 95% CI, 0.69-0.99; P = .04). When
comparing included cases with those with no follow-up, we noted minor differences in several
characteristics (eTable 5 in Supplement 1). None of these differences suggested a substantial bias
resulting from the exclusion of patients without complete follow up. Apart from the lost to follow up,
the number of missing baseline covariates was 185 (0.6%) for ASA score and 2189 (5.8%) for BMI.
Discussion
Principal Findings
The results of this real-life cohort study show an overall unchanged SSI risk when SAP was
administered as a double dose. In multivariable models, we found significant interactions with both
weight categories and wound contamination classes. In the weight category–stratified models, SSI
rates were 20% lower with the higher dose for patients weighing at least 80 and less than 90 kg, but
significant differences were not observed in any of the higher weight categories. Second, in the
models stratified by wound contamination class, SSI rates were 50% lower in patients with
contaminated wounds but not with clean or clean-contaminated wounds.
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Regarding the decreased risk in surgical procedures with the contaminated wound class, a
previous meta-analysis22 identified a 46% lower SSI rate for certain intra-abdominal surgical
procedures in which multiple SAP doses were administered vs a single dose. Therefore, the lower SSI
rate in this wound contamination class category with the double dose may reflect the higher single-
dose SAP or even a need for therapeutic (or at least prolonged) rather than single-dose prophylactic
antimicrobial treatment. Of note, a recent meta-analysis23 found no evidence of benefit for an overall
postoperative continuation of SAP. Our analysis was also not designed to answer whether single-
dose or repeated SAP administration for contaminated wound surgery were associated with a
differential SSI rate.
Table 3. Fully Adjusted Mixed-Effects Logistic Regression Models With Surgical Site Infection
as the Dependent Variablea
Variable aOR (95% CI) P value
Cefuroxime dose
Single 1 [Reference] NA
Double 0.89 (0.78-1.02) .10
BMI (per unit) 1.05 (1.04-1.07) <.001
Age (per year) 1.00 (1.00-1.01) .63
Sex
Female 1 [Reference] NA
Male 1.16 (0.99-1.35) .06
ASA score
1-2 1 [Reference] NA
3-5 1.48 (1.27-1.72) <.001
Wound contamination class
Clean 1 [Reference] NA
Clean-contaminated 0.76 (0.31-1.83) .54
Contaminated 1.07 (0.44-2.60) .88
Elective surgery
No 1 [Reference] NA
Yes 0.76 (0.63-0.92) .004
Timing of SAP before incision (per 30 min) 0.92 (0.84-1.00) .06
Duration exceeding standard time
No 1 [Reference] NA
Yes 1.55 (1.35-1.78) <.001
Year
2015 1 [Reference] NA
2016 1.07 (0.79-1.44) .68
2017 1.18 (0.88-1.59) .28
2018 1.25 (0.92-1.69) .15
2019 1.21 (0.86-1.70) .27
Hospital size, beds
<200 1 [Reference] NA
200-499 1.24 (1.07-1.43) .004
≥500 1.12 (0.92-1.35) .26
Abbreviations: aOR, adjusted odds ratio; ASA,
American Society of Anesthesiologists; BMI, body
mass index (calculated as weight in kilograms divided
by height in meters squared); NA, not applicable; SAP,
surgical antimicrobial prophylaxis.
a Procedure type was added as a random effect. Only
complete cases (ie, 35 268 of 37 640 [93.7%])
included.
Table 4. Results of Adjusted Mixed-Effects Logistic Models, Stratified by Weight Category
Weight category, kg Patients, No.a aOR (95% CI)b P value
80 to <90 15 664 0.76 (0.61-0.97) .02
90 to <100 9640 1.12 (0.87-1.47) .37
100 to <120 7522 0.99 (0.76-1.30) .96
≥120 2388 0.65 (0.42-1.01) .06
Abbreviation: aOR, adjusted odds ratio.
a Complete cases only.
b Estimates are provided for the association of double
dose cefuroxime (3.0 g) with surgical site infection;
ie, reference category is single-dose cefuroxime
(1.5 g).
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The interpretation of the lower rate among patients weighing 80 to 90 kg is more complicated
and may simply represent a spurious finding. However, a hypothesis for the significantly lower rate
could be that this weight category benefits from the higher dose24 without being overridden by the
higher SSI risk associated with increased weight.4,8,17,25 In addition, it has been shown that cefazolin
tissue concentration is reduced with increasing weight, and therefore, even higher doses may be
required for individuals weighing more than 90 kg,26 while mean serum concentrations remained
similar independent of the weight category.12
Our primary exposure variable was single- vs double-dose SAP administration. However, our
data show that factors other than timing of SAP administration were significantly associated with SSI
risk. Increased weight, higher ASA score, and unplanned procedures were strongly associated with
an increased risk.17
Internal and External Validity
We believe the internal validity or our study to be excellent, as hospitals throughout Switzerland
participated, including smaller institutions (<200 beds) and large centers (>500 beds). The
multilevel analysis with clustering at the intervention level allowed us to control for potential
variation in SSI rate between different surgical procedures. In addition, we adjusted for hospital size
and individual factors (age, ASA score, duration of surgery) that might have been a possible source of
bias. Uniform SAP recommendations for Switzerland were introduced in 2015. Antimicrobial
resistance rates (eg, methicillin-resistant Staphylococcus aureus, extended spectrum β-lactamase)
are low throughout the country, not requiring broader empirical SAP coverage. Therefore, it is
unlikely that centers varied their SAP protocols significantly according to their local epidemiology.
Strengths of our study were the large sample size, standardized evaluation of SSI cases by
dedicated nurses and physicians, postdischarge surveillance at 30 days (or 1 year for implant surgery)
and a less than 9% loss to follow-up. In addition, our study involved routine on-site monitoring of the
data collection quality and a multilevel model that allowed adjustment for different surgical
procedures.
Concerning external validity, the analysis of large prospective registries may be the ideal source
for generating high-quality scientific data.27 Our results did not confirm a preliminary study that
suggested an approximately 4-fold lower SSI risk among patients weighing at least 80 kg who
received a double cefuroxime dose.16 The 4-fold lower rate is unlikely to be physiological, and
therefore, previous studies may not have corrected for significant, unrecognized bias.
Clinical Implications
Our results suggest that general routine administration of a double SAP dose in patients weighing at
least 80 kg has no general additional benefit. The observed signal in the weight category of 80 to
90 kg and the lower rate in patients with contaminated wounds and in surgical procedures without
implants must be further confirmed. Given its minor toxic effects8 and the significant association in 2
stratified analysis, application of double-dose cefuroxime SAP in patients weighing at least 80 kg
merits further considerations.
Research Implications
To definitively answer the question of whether a dose increase may lower SSI rate in patients
weighing at least 80 kg and for this strategy to become standard practice, randomized clinical trials
are needed. In consideration of the very large sample size of the present cohort study, this will be
hard to achieve.
Limitations
This study has limitations. The main limitation was that variables were predefined by the SSI
surveillance program. Important patient comorbidities and characteristics, such as diabetes,
JAMA Network Open | Infectious Diseases Double-Dose Cefuroxime and Surgical Site Infections in Patients Weighing 80 kg or More
JAMA Network Open. 2021;4(12):e2138926. doi:10.1001/jamanetworkopen.2021.38926 (Reprinted) December 15, 2021 8/11
Downloaded From: https://jamanetwork.com/ by a E-Library Insel User  on 12/20/2021
smoking, nutritional status, intraoperative temperature, oxygen measurements, and continued
antimicrobial prophylaxis, were not available.
As this was a real-life cohort study, there may have been confounding by indication, which could
have led to underestimation of a significant association of double-dose SAP. The results may have
been biased by including procedures with implants and a 1-year follow up. When excluding these
patients, double-dose cefuroxime was significantly associated with a lower SSI rate. These patients
may be more prone to infection independent of the exposure to different doses of surgical
antimicrobial prophylaxis.
We also lacked information on individual surgeons as well as on individual decisions regarding
when single or double doses were administered. In addition, there were no serum or tissue
cefuroxime levels available. We did not assess toxic effects or antimicrobial agent serum
concentrations that were associated with the 2 different doses. As routine susceptibility of
microorganisms was not available, we were not able to assess the association between the dose of
cefuroxime SAP and cefuroxime-susceptibility of microorganisms identified.
Conclusions
In this study, double-dose cefuroxime SAP in patients weighing at least 80 kg was not consistently
associated with a lower SSI rate. The lower SSI rate within the weight category of 80 to less than 90
kg, for contaminated wound class, and for surgical procedures without implants merits further
investigation.
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